Beule, N. de

patient response chemotherapy treatment pcv chemotherapy study response rate cycle tumor oligodendroglioma od tumors second-line anaplastic temozolomide center phase objective response rate cancer progression month second-line chemotherapy toxicity oligodendroglial tumors pathology review anaplastic astrocytoma radiation therapy trial pathology review oncol disease phase ii studies first-line pcv chemotherapy netherland criteria van den anaplastic oligodendroglioma oligodendroglial 12 months result oligoastrocytoma second-line treatment chinot tumor progression radiation astrocytoma evaluable grade neurology procarbazine vincristine first-line resonance imaging dose reductions 28 days methylating agent department cairncross jg astrocytic tumors first-line pcv hepatic function 12 cycles dose intensity 8.0 months 24 patients lomustine series eortc therapy kros jm objective survival neuro-oncology macdonald performance status barrie m end point oncology world health organisation status